Soliris is currently approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Sixty-three percent of patients achieved a complete and stable response that allowed them to discontinue all immunotherapies.
Patients who underwent surgery also experienced lower distress levels from treatment-related symptoms.
The guidelines are the result of a consensus of an international task force of MG experts.
Treatment has been linked to durable, symptom-free, treatment-free remission in several cases of MG.
Neurology Advisor Articles
- Minocycline May Slow Progression From Clinically Isolated Syndrome to Multiple Sclerosis
- Brain Inflammation Observed in Obsessive-Compulsive Disorder
- Extended-Release Amantadine Reduces Levodopa-Induced Dyskinesia in Parkinson's Disease
- Growing Old Without Alzheimer's Pathology: What's the Secret?
- Traumatic Brain Injury May Increase Later Risk of Dementia